FindTrial
Sign In

ICP-022

DRUG10 trials

Sponsors

Innocare Pharma Australia Pty Ltd, Beijing InnoCare Pharma Tech Co., Ltd., Henan Cancer Hospital

Conditions

CLL/SLLCentral Nervous System LymphomaChronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaMZLMantle Cell LymphomaPCNSLRheumatoid Arthritis

Phase 1

A Phase I Study of ICP-022 in Healthy Subjects
CompletedNCT03189017
Innocare Pharma Australia Pty LtdRheumatoid Arthritis, Systemic Lupus Erythematosus
Start: 2017-07-03End: 2018-10-30Updated: 2019-08-01
A Study to Evaluate ICP-022 in Patients With CLL/ SLL
NCT03493217
Beijing InnoCare Pharma Tech Co., Ltd.CLL/SLL
Start: 2018-04-17End: 2022-12-31Target: 100Updated: 2022-07-06
A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
CompletedNCT03494179
Beijing InnoCare Pharma Tech Co., Ltd.Mantle Cell Lymphoma
Start: 2018-04-02End: 2020-04-10Updated: 2026-06-08
A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
CompletedNCT04305197
Beijing InnoCare Pharma Tech Co., Ltd.Systemic Lupus Erythematosus
Start: 2020-07-09End: 2022-04-28Updated: 2022-11-30

Phase 2

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
CompletedNCT03797456
Beijing InnoCare Pharma Tech Co., Ltd.MZL
Start: 2019-04-01End: 2024-02-06Updated: 2024-04-18
A Study of ICP-022 in Patients With R/R DLBCL
CompletedNCT04438005
Beijing InnoCare Pharma Tech Co., Ltd.Diffuse Large B Cell Lymphoma
Start: 2020-05-07End: 2021-12-13Updated: 2024-05-13
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
NCT04438044
Beijing InnoCare Pharma Tech Co., Ltd.PCNSL, Secondary Central Nervous System Lymphoma
Start: 2019-06-18End: 2023-12-31Updated: 2022-10-12
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
CompletedNCT04440059
Beijing InnoCare Pharma Tech Co., Ltd.Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
Start: 2019-08-10End: 2024-01-09Updated: 2024-04-18
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
RecruitingNCT05209620
Henan Cancer HospitalCentral Nervous System Lymphoma
Start: 2021-12-21End: 2026-12-21Target: 30Updated: 2025-04-23

Phase 3

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
NCT04578613
Beijing InnoCare Pharma Tech Co., Ltd.Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Start: 2021-01-08End: 2025-06-30Target: 218Updated: 2023-06-05

Related Papers

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.
2026-07-06
Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study.
2026-05-29
Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.
2024-11-124 citations
Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results
Blood2023-11-024 citations
Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up
Blood2023-11-021 citations
Orelabrutinib, a new‐generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma
Hematological Oncology2023-06-01
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
Blood Advances2023-04-2022 citations
Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)
Blood2022-11-158 citations
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-Naïve Patients with Mcd Subtype Diffuse Large B-Cell Lymphoma
Blood2022-11-153 citations
Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.
2022-10-0426 citations
Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study
Blood2021-11-0515 citations